Danish Pharmacovigilance Update, 20 October 2011

09 November 2011

In this issue of Danish Pharmacovigilance Update:

  • Use of medicines involving a risk of serious and life-threatening skin reactions
  • European Medicines Agency (EMA) to investigate the possible connection between orlistat and rare cases of severe liver toxicity
  • EMA completes review of peritoneal dialysis solutions from Baxter A/S
  • Product information for Revlimid® to be updated
  • The Danish Medicines Agency has received a report of a death in connection with use of the smoking cessation product Champix®
  • List of medicines most frequently involved in serious adverse drug events to help minimise risks in the medication process
  • New restrictions in use, further contraindications and warnings for Multaq® (dronedarone)
  • Adverse reactions in connection with the childhood immunisation programme in the first half of 2011

Download the newsletter in the box to the right.

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.